Non-Invasive Prenatal Testing Industry (US, Europe, China, Japan) 2030 Forecasts

The global Non-Invasive Prenatal Testing Market is forecasted to reach USD 8.75 Billion by 2027, according to a new report by Emergen Research. Non-invasive prenatal testing (NIPT), commonly known as cell-free DNA testing, is regarded as a significant extension to the variety of diagnostic methods used to detect fetal chromosome defects.

Read More; https://www.emergenresearch.co....m/industry-report/no

NIPT is also considered superior to other screening modalities, particularly for trisomy 21 (one of the most prevalent congenital anomalies). NIPT enables individuals to make informed decisions as to whether diagnostic testing should be carried out. Associated fetal chromosomal anomalies typically include the benefit or lack of genetic material that can differ from small segments to small segments of chromosomes to entire chromosomes.